377091-18-4

Usage

Appearance

White solid

Molecular weight

259.96 g/mol

Functional groups

Bromine atoms, ethoxy group, benzene ring

Usage

Intermediate in organic synthesis, building block for other organic compounds

Applications

Pharmaceuticals, agrochemicals, materials science

Reactivity

Versatile due to functional groups

Safety precautions

Handle with care due to potentially hazardous nature

Upstream product

• 28165-52-8 2,5-dibromophenol 
• 106-93-4 ethylene dibromide 
• 1435-52-5 2,5-dibromofluorobenzene 
• 377091-17-3 1,4-dibromo-2-hydroxyethoxybenzene 

Downstream Products

• 66826-78-6 5-bromo-2,3-dihydrobenzo[b]furan 
• 1156406-00-6 6-diphenylphosphino-2,3-dihydrobenzofuran 
• 55745-96-5 2,3-dihydro-1-benzofuran-6-carbaldehyde 
• 1083168-69-7 (2,3-dihydrobenzofuran-6-yl)methanol 
• 55746-20-8 (2,3-dihydrobenzofuran-6-yl)methanamine 
• 1345120-28-6 N-[5-(5-chloro-2,3-dihydrobenzo[b]furan-6-yl)pyrazin-2-yl](2,6-difluorophenyl)carboxamide 
• 1345120-21-9 N-[5-(5-chloro(2,3-dihydrobenzo[3,4-b]furan-6-yl))(2-pyridyl)](2-fluorophenyl)carboxamide 
• 1345120-15-1 N-[5-(5-chloro(2,3-dihydrobenzo[3,4-b]furan-6-yl))(2-pyridyl)](2,6-difluorophenyl)carboxamide 

Relevant academic research and scientific papers

SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, L, Z, Q1, Q2 and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS

Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

FUSED GLYCOSIDASE INHIBITORS

Compounds of formula (I), wherein A, Z, E, R1, R2, m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

ANNULATED GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

LINEAR GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, L, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

5,5-DIFLUORO- AND 5-FLUORO-5-METHYL-C-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS

The present invention is directed to 5,5-difluoro- and 5-fluoro-5-methyl-C-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES

The invention relates to a process for preparing either enantiomer of a compound of formula (I), wherein X, Y and n have the meaning given in claim 1, with high enantiomeric excess (e.e.), by chiral resolution in the presence of a non-racemic, chiral acid.

Heterocyclic compound

The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.